These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 9689484

  • 1. Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease.
    Münch G, Cunningham AM, Riederer P, Braak E.
    Brain Res; 1998 Jun 15; 796(1-2):307-10. PubMed ID: 9689484
    [Abstract] [Full Text] [Related]

  • 2. Possible implication of hippocampal cholinergic neurostimulating peptide (HCNP)-related components in Hirano body formation.
    Mitake S, Katada E, Otsuka Y, Matsukawa N, Iwase T, Tsugu T, Fujimori O, Ojika K.
    Neuropathol Appl Neurobiol; 1996 Oct 15; 22(5):440-5. PubMed ID: 8930956
    [Abstract] [Full Text] [Related]

  • 3. Caspase-cleaved actin (fractin) immunolabelling of Hirano bodies.
    Rossiter JP, Anderson LL, Yang F, Cole GM.
    Neuropathol Appl Neurobiol; 2000 Aug 15; 26(4):342-6. PubMed ID: 10931367
    [Abstract] [Full Text] [Related]

  • 4. Hirano bodies contain tau protein.
    Galloway PG, Perry G, Kosik KS, Gambetti P.
    Brain Res; 1987 Feb 17; 403(2):337-40. PubMed ID: 3103867
    [Abstract] [Full Text] [Related]

  • 5. Hirano bodies and Alzheimer's disease.
    Mitake S, Ojika K, Hirano A.
    Kaohsiung J Med Sci; 1997 Jan 17; 13(1):10-8. PubMed ID: 9130818
    [Abstract] [Full Text] [Related]

  • 6. The presence of FAC1 protein in Hirano bodies.
    Jordan-Sciutto K, Dragich J, Walcott D, Bowser R.
    Neuropathol Appl Neurobiol; 1998 Oct 17; 24(5):359-66. PubMed ID: 9821166
    [Abstract] [Full Text] [Related]

  • 7. Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer's disease.
    Wong A, Lüth HJ, Deuther-Conrad W, Dukic-Stefanovic S, Gasic-Milenkovic J, Arendt T, Münch G.
    Brain Res; 2001 Nov 30; 920(1-2):32-40. PubMed ID: 11716809
    [Abstract] [Full Text] [Related]

  • 8. Effect of advanced glycation endproducts on cell cycle and their relevance for Alzheimer's disease.
    Münch G, Gasic-Milenkovic J, Arendt T.
    J Neural Transm Suppl; 2003 Nov 30; (65):63-71. PubMed ID: 12946049
    [Abstract] [Full Text] [Related]

  • 9. Neuronal and glial advanced glycation end product [Nepsilon-(carboxymethyl)lysine]] in Alzheimer's disease brains.
    Takeda A, Wakai M, Niwa H, Dei R, Yamamoto M, Li M, Goto Y, Yasuda T, Nakagomi Y, Watanabe M, Inagaki T, Yasuda Y, Miyata T, Sobue G.
    Acta Neuropathol; 2001 Jan 30; 101(1):27-35. PubMed ID: 11194938
    [Abstract] [Full Text] [Related]

  • 10. Hirano body filaments contain actin and actin-associated proteins.
    Galloway PG, Perry G, Gambetti P.
    J Neuropathol Exp Neurol; 1987 Mar 30; 46(2):185-99. PubMed ID: 3029338
    [Abstract] [Full Text] [Related]

  • 11. Sequestration of tubulin in neurons in Alzheimer's disease.
    Price DL, Altschuler RJ, Struble RG, Casanova MF, Cork LC, Murphy DB.
    Brain Res; 1986 Oct 22; 385(2):305-10. PubMed ID: 3096492
    [Abstract] [Full Text] [Related]

  • 12. Analysis of epitopes shared by Hirano bodies and neurofilament proteins in normal and Alzheimer's disease hippocampus.
    Schmidt ML, Lee VM, Trojanowski JQ.
    Lab Invest; 1989 Apr 22; 60(4):513-22. PubMed ID: 2468822
    [Abstract] [Full Text] [Related]

  • 13. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease.
    Takeuchi M, Yamagishi S.
    Curr Pharm Des; 2008 Apr 22; 14(10):973-8. PubMed ID: 18473848
    [Abstract] [Full Text] [Related]

  • 14. Glycation and microglial reaction in lesions of Alzheimer's disease.
    Dickson DW, Sinicropi S, Yen SH, Ko LW, Mattiace LA, Bucala R, Vlassara H.
    Neurobiol Aging; 1996 Apr 22; 17(5):733-43. PubMed ID: 8892346
    [Abstract] [Full Text] [Related]

  • 15. Transgenic mouse model for the formation of Hirano bodies.
    Ha S, Furukawa R, Stramiello M, Wagner JJ, Fechheimer M.
    BMC Neurosci; 2011 Oct 06; 12():97. PubMed ID: 21978358
    [Abstract] [Full Text] [Related]

  • 16. Advanced glycation endproducts in ageing and Alzheimer's disease.
    Münch G, Thome J, Foley P, Schinzel R, Riederer P.
    Brain Res Brain Res Rev; 1997 Feb 06; 23(1-2):134-43. PubMed ID: 9063589
    [Abstract] [Full Text] [Related]

  • 17. The cytosolic inclusion bodies that consist of splice variants that lack exon 5 of the presenilin-2 gene differ obviously from Hirano bodies observed in the brain from sporadic cases of Alzheimer's disease patients.
    Manabe T, Katayama T, Sato N, Kudo T, Matsuzaki S, Imaizumi K, Tohyama M.
    Neurosci Lett; 2002 Aug 09; 328(2):198-200. PubMed ID: 12133587
    [Abstract] [Full Text] [Related]

  • 18. Localization of identified advanced glycation end-product structures, N epsilon(carboxymethyl)lysine and pentosidine, in age-related inclusions in human brains.
    Kimura T, Takamatsu J, Miyata T, Miyakawa T, Horiuchi S.
    Pathol Int; 1998 Aug 09; 48(8):575-9. PubMed ID: 9736403
    [Abstract] [Full Text] [Related]

  • 19. Ubiquilin-1 immunoreactivity is concentrated on Hirano bodies and dystrophic neurites in Alzheimer's disease brains.
    Satoh J, Tabunoki H, Ishida T, Saito Y, Arima K.
    Neuropathol Appl Neurobiol; 2013 Dec 09; 39(7):817-30. PubMed ID: 23421764
    [Abstract] [Full Text] [Related]

  • 20. Hirano bodies accumulate C-terminal sequences of beta-amyloid precursor protein (beta-APP) epitopes.
    Munoz DG, Wang D, Greenberg BD.
    J Neuropathol Exp Neurol; 1993 Jan 09; 52(1):14-21. PubMed ID: 7678852
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.